米托蒽醌
| 中文名称 | 米托蒽醌 |
|---|---|
| 中文同义词 | 1,4-二羟基-5,8-双[[2-[(2-羟乙基)氨基]乙基]氨基]-9,10-蒽醌;米托蒽醌(米托恩醌、米拖蒽醌);盐酸米托蒽醌 (HPLC);米拖蒽醌;米托恩醌;米托蒽醌;1,4-二羟基-5,8-二[[2-[(2-羟基乙基)氨基]乙基]氨基]蒽-9,10-二酮;米托蒽醌对照品 MITOXANTRONE |
| 英文名称 | Mitoxantrone |
| 英文同义词 | MITOXANTRONE;1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedi;1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione;Mitoxantrone (base and/or unspecified salts);MITOXANTRONUM;1,4-Dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethylamino]-9,10-anthraquinone;MitoxantroneBase;Mitoxantrone Hcl 70476-82-3 / Base |
| CAS号 | 65271-80-9 |
| 分子式 | C22H28N4O6 |
| 分子量 | 444.48 |
| EINECS号 | 1533716-785-6 |
| 相关类别 | 有机原料;小分子抑制剂，天然产物;精细化工;细胞生物学试剂;生化试剂;抑制剂;Pharmaceutical material and intermeidates;Intermediates & Fine Chemicals;Pharmaceuticals;Anti-cancer&immunity;Inhibitors;APIs;API |
| Mol文件 | 65271-80-9.mol |
| 结构式 |  |
米托蒽醌 性质
| 熔点 | 170-1740C |
|---|---|
| 沸点 | 554.47°C (rough estimate) |
| 密度 | 1.3049 (rough estimate) |
| 折射率 | 1.6500 (estimate) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | DMSO（少量）、甲醇（少量）、水（少量） |
| 酸度系数(pKa) | pKa 5.99 (Uncertain);8.13 (Uncertain) |
| 形态 | 固体 |
| 颜色 | 深蓝色到黑色 |
| InChI | InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 |
| InChIKey | KKZJGLLVHKMTCM-UHFFFAOYSA-N |
| SMILES | C1(O)=C2C(C(=O)C3=C(C2=O)C(NCCNCCO)=CC=C3NCCNCCO)=C(O)C=C1 |
| CAS 数据库 | 65271-80-9(CAS DataBase Reference) |
| (IARC)致癌物分类 | 2B (Vol. 76) 2000 |
|
PKC 8.5 μM (IC 50 ) |
Topoisomerase II
|
Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 μg/mL) induces a decrease in cell viability. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC 50 values of 18 and 196 nM, respectively.
Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produces a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also shows effective antitumor activities and produces a 60% and a 45% ILS, respectively..
安全信息
| 危险品标志 | T,T+ |
|---|---|
| 危险类别码 | 46-61-26/27/28 |
| 安全说明 | 53-36/37/39-45-22 |
| WGK Germany | 3 |
| RTECS号 | CB5748500 |
| 海关编码 | 2922.50.2500 |
米托蒽醌 化学药品说明书
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/02/08 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 25 mg | 371元 |
| 2025/02/08 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 10mM * 1mLin DMSO | 408元 |